Login
$FTH
$9.23 -$0.05 (0.54%) After hours

$FTH SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
13 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 8-K: Other Events

FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026 Exhibit 99.1

09 Nov 2026 8-K: Regulation FD Disclosure

Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

03 Nov 2026 Form 4: Parikh Anand Kiran, Director

Gave 100,000 shares as a gift · Acquired 100,000 shares (Gift)

03 Nov 2026 S-8
03 Nov 2026 8-K: Results of Operations and Financial Condition

Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end

03 Nov 2026 10-Q
27 Oct 2026 Form 4: Schayowitz Adam, Director

Granted 25,000 Stock Option (right to buy)

27 Oct 2026 Form 3: Schayowitz Adam, Director

No securities owned

27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

17 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Sep 2026 Form 4: Vousden Karen H, Director

Granted 25,000 Stock Option (right to buy)

15 Sep 2026 Form 3: Vousden Karen H, Director

Holds 42,631 shares of Common Stock

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 144
04 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support